Shopping Cart
- Remove All
Your shopping cart is currently empty
StA-IFN-1 is an inhibitor of the interferon (IFN) induction pathway with an IC50 value of 4.1 μM in a GFP reporter assay for IFN induction similar to TPCA-1 , which specifically inhibits the IKKβ component of the IFN induction pathway. It does not show inhibitory activity in a GFP reporter assay for IFN signaling in which ruxolitinib , which is specific for the IFN signaling component JAK1, is active. StA-IFN-1 reduces the levels of IFN-β, but not ISG MxA, mRNA, suggesting that it is selective for the IFN induction pathway and not the IFN signaling pathway.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $198 | 35 days | |
| 5 mg | $845 | 35 days | |
| 10 mg | $1,580 | 35 days |
| Description | StA-IFN-1 is an inhibitor of the interferon (IFN) induction pathway with an IC50 value of 4.1 μM in a GFP reporter assay for IFN induction similar to TPCA-1 , which specifically inhibits the IKKβ component of the IFN induction pathway. It does not show inhibitory activity in a GFP reporter assay for IFN signaling in which ruxolitinib , which is specific for the IFN signaling component JAK1, is active. StA-IFN-1 reduces the levels of IFN-β, but not ISG MxA, mRNA, suggesting that it is selective for the IFN induction pathway and not the IFN signaling pathway. |
| Molecular Weight | 255.27 |
| Formula | C14H13N3O2 |
| Cas No. | 300839-31-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: 5 mg/mL (19.59 mM), Sonication is recommended. DMF: 3 mg/mL (11.75 mM), Sonication is recommended. DMSO:PBS (pH 7.2) (1:10): 0.1 mg/mL (0.39 mM), Sonication is recommended. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.